Tamiflu (Oseltamivir Phosphate) is primarily used as antiviral drug for treating influenza. It works by inhibiting the viral neuraminidase enzyme, thus preventing the further spread of the flu virus in the body. With rising prevalence of influenza globally, demand for effective treatment options has increased substantially. Tamiflu reduces the duration of influenza symptoms and prevents complications if taken within 48 hours of onset of symptoms.
The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growth of the Tamiflu (Oseltamivir Phosphate) market is being accelerated by rising awareness regarding treatment options for influenza. Various government initiatives aimed at educating the masses about influenza prevention and management have contributed significantly to increasing diagnosis rates. Subsequently, more patients are opting for antiviral drugs such as Tamiflu (Oseltamivir Phosphate) to reduce the severity and duration of flu symptoms. Manufacturers are engaged in new product launches and expansion of production facilities to cater to growing demand. For instance, F. Hoffman La Roche launched a new generic version of Tamiflu 75mg capsules in 2019 to increase access and affordability.
Segment Analysis
Tamiflu is segmented into two types capsules and oral suspension, of which capsules dominates the market followed by oral suspension. The presence of established manufacturing process and ease of administration drive the demand for capsules segment. Capsules provide controlled release of the active pharmaceutical ingredient and enables uniform dosing which makes them a preferred choice over oral suspensions.
Key Takeaways
The Global Tamiflu Market Size is expected to witness high growth over the forecast period. Growing prevalence of influenza diseases worldwide is anticipated to propel the demand for Tamiflu. According to WHO estimates, there are around 1 billion cases of influenza reported annually around the globe. Increasing government initiatives to spread awareness about influenza prevention and treatment is also boosting the market growth. The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030.
Regional analysis
North America is currently the largest market for Tamiflu accounting for over 30% of the global revenue. High per capita healthcare expenditure and increasing inclination towards seasonal flu vaccination in the US and Canada are some of the key factors driving the North America market. Asia Pacific is projected to witness the fastest growth owing to large patient pool, improving healthcare infrastructure and rising medical tourism in the region.
Key players
The global Tamiflu market is moderately consolidated in nature with few players holding major share. Key players operating in the market are HCA Healthcare, Ascension Health, Kaiser Permanente, and Mayo Clinic. These players are focusing on new product approvals and launches to expand their product portfolio and strengthen market position. In 2021, Roche received USFDA approval for generic version of Tamiflu, providing more affordable treatment options to patients.
Get more insights on this topic:
https://www.dailyprbulletin.com/tamiflu-oseltamivir-phosphate-market-analysis/
Check below trending articles related to this topic:
https://wotpost.com/in-sync-with-life-exploring-the-promise-of-modern-cardiac-assist-advancements/
Explore more trending article related to this topic:
https://wotpost.com/wireless-waves-weaving-navigating-the-landscape-of-land-mobile-radio-systems/
Comments
0 comment